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Abstract
HIV-1 integrates more frequently into transcribed genes, however the biological significance
of HIV-1 integration targeting has remained elusive. Using a selective high-throughput
chemical screen, we discovered that the cardiac glycoside digoxin inhibits wild-type HIV-1
infection more potently than HIV-1 bearing a single point mutation (N74D) in the capsid pro-
tein. We confirmed that digoxin repressed viral gene expression by targeting the cellular
Na+/K+ ATPase, but this did not explain its selectivity. Parallel RNAseq and integration map-
ping in infected cells demonstrated that digoxin inhibited expression of genes involved in T-
cell activation and cell metabolism. Analysis of >400,000 unique integration sites showed
that WT virus integrated more frequently than N74D mutant within or near genes susceptible
to repression by digoxin and involved in T-cell activation and cell metabolism. Two main
gene networks down-regulated by the drug were CD40L and CD38. Blocking CD40L by
neutralizing antibodies selectively inhibited WT virus infection, phenocopying digoxin. Thus
the selectivity of digoxin depends on a combination of integration targeting and repression
of specific gene networks. The drug unmasked a functional connection between HIV-1 inte-
gration and T-cell activation. Our results suggest that HIV-1 evolved integration site selec-
tion to couple its early gene expression with the status of target CD4+ T-cells, which may
affect latency and viral reactivation.
Author summary
HIV-1 integrates more frequently within transcribed host genes, however we do not
understand the biological significance of this. We found that a drug called digoxin inhibits
wild type HIV-1 more potently than an HIV-1 bearing a single point mutation in the
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capsid protein. Here we show that digoxin represses HIV-1 gene expression and in parallel
inhibits CD4+ T-cell activation and metabolism. When we analysed the integration sites
of wild type and mutant HIV-1, we discovered that wild type virus integrates within or
near genes involved in CD4+ T-cell activation and metabolism more often than the
mutant virus. Because these are the very same genes repressed by digoxin, the integration
bias of wild type virus makes it more susceptible than mutant virus to silencing by the
drug. Digoxin unmasked a functional link between HIV-1 integration and T-cell activa-
tion, which may affect HIV-1 latency and reactivation.
Introduction
HIV-1 infects immune cells expressing CD4 and CCR5/CXCR4, which serve as HIV-1 recep-
tor and co-receptor for entry, such as helper T-lymphocytes and macrophages. Upon entry
and reverse transcription, the virus must access the nucleus of infected cells and integrate into
host chromosomes, however little is known about the steps occurring between nuclear entry
and integration. The HIV-1 capsid protein (CA) was shown to be a dominant determinant of
nuclear import [1]. Several studies have since indicated that CA is involved in nuclear entry
and post-nuclear entry events (reviewed in [2]). CA interacts with nucleoporins Nup153
[3,4,5,6] and Nup358, via the CypA binding domain [7,8,9], although the significance of this
interaction is unclear [10]. CA also interacts with the mRNA processing factor CPSF6 and
with the nuclear transport receptor Transportin 3 (TNPO3), which were shown to be impor-
tant for HIV-1 pre- and post-nuclear entry steps [11,12,13,14,15]. Small amounts of HIV-1 CA
have been detected inside the nuclei by biochemical fractionation [15], and the antibiotic Cou-
mermycin-A1 was shown to impair HIV-1 integration by targeting CA [16]. These observa-
tions led to the proposal that CA is involved in post-nuclear entry steps leading to efficient
integration [15]. Imaging approaches have shown that nuclear CA is associated with viral
nucleic acids [17,18,19] and Coumermycin-A1 was reported to block integration by prevent-
ing the completion of virus uncoating inside the nucleus [20]. HIV-1 preferentially integrates
within actively transcribed genes [21,22]. Remarkably, CA binding to CPSF6 in the nucleus is
critical for targeting HIV-1 integration near transcribed genes, whereas binding of host factor
LEDGF/p75 to HIV-1 integrase seems more important for integration targeting within tran-
scribed genes [23,24].
Certain CA point mutations, such as N74D, are independent of Nup358, Nup153, CPSF6
and TNPO3 for infection, and show a different integration site selection compared to wild
type virus [7,23,25]. This indicates that a single point mutation in CA can change the usage of
HIV-1 host factors during the early steps of infection, resulting in an altered integration pat-
tern. However the functional significance of this altered integration distribution is unclear.
To gain greater insight into these steps of the HIV-1 life cycle, we have taken advantage of
the differences between wild type (WT) and N74D mutant CA to design a novel high through
put screening assay whereby CD4+ T-cells are co-infected with WT and N74D single cycle
HIV-1 vectors, which are identical except for the CA point mutation. The WT virus expresses
GFP whereas N74D expresses mCherry. Compound libraries are screened to find selective hits
that inhibit WT more than N74D. These hits are then used to identify target molecules that
affect—directly or indirectly—the interaction between host factors and HIV-1 CA and impair
early events of infection.
Here, using this novel screening approach, we found that the cardiac glycoside digoxin
inhibits WT more potently than N74D virus. We confirmed that digoxin inhibited viral gene
A functional link between HIV-1 integration and T-cell activation
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expression by targeting the Na+/K+ ATPase [26] but this did not explain its selectivity. To
determine the basis for the selectivity of digoxin we performed, in parallel, RNAseq and high-
throughput integration site analysis in cells treated with the drug. The results showed that
digoxin down-regulates genes involved in T-cell activation and cell metabolism. We found
that WT virus, but not N74D virus, preferentially integrates into such genes and is affected by
their repression. Therefore, using digoxin to acutely perturb specific gene expression path-
ways, we uncovered a functional link between HIV-1 integration preference, viral gene expres-
sion and T-cell activation and metabolism.
Results
Digoxin inhibits infection by WT virus more potently than N74D virus
We designed a novel high through put screening workflow to investigate the early events of
HIV-1 replication that are influenced by CA (Fig 1A). Jurkat CD4+ T-cells were co-infected
with two VSV-G pseudotyped single cycle HIV-1 vectors, one containing WT CA and express-
ing GFP (WT-GFP), and another containing the CA N74D mutation and expressing mCherry
(N74D-CHE). We aimed to identify small compounds that inhibited WT virus infection at
least 50% of control (DMSO) with little inhibition of N74D virus infection ("selective hits").
The rationale for this assay was based on the different usage of host cell factors by WT and
N74D viruses [4,7,27]: selective hits were likely to target either the WT CA protein itself or
host cell factors interacting preferentially with WT over N74D virus, directly or indirectly.
After optimization, the assay had a Z’ score offfi0.7, and the number of cells infected with each
type of virus, and cell survival, were both determined 24 hours post-infection by dual colour
flow cytometry. The National Institute of Neurological Diseases and Stroke small-compound
library was used to perform the screening at a final concentration of 1 μM (S1 File). This
library contains 1041 compounds and includes many FDA-approved drugs. We detected eigh-
teen selective hits belonging to different chemical and pharmacological classes (S1 File and S1
Table): four were anti-inflammatory, hinting that WT and N74D virus may be differentially
susceptible to innate immune responses [28] and two were cardiac glycosides sharing a similar
chemical structure: digoxin and digitoxin.
We focused on the cardiac glycosides because of the low probability of identifying by
chance two hits with the same phenotype that share a similar chemical structure. Furthermore,
digoxin was reported previously to exert potent antiretroviral activity by reducing HIV-1 gene
expression [29,30], validating our screening. However, because of the different design, previ-
ous screenings did not detect the CA-dependent selectivity of digoxin, which is the focus of
this study.
To confirm our screening results, we re-examined the selectivity of digoxin in single cycle
infectious assays using WT-GFP or N74D-CHE HIV-1 vectors. Digoxin inhibited WT more
than N74D virus whereas the integrase inhibitor raltegravir inhibited each virus equally (Fig
1B). To control that the observed phenotype did not depend on the specific fluorescent marker
expressed by each vector (GFP or CHE), we reversed the markers and infected Jurkat cells
with WT-CHE and N74D-GFP vectors. First, we titrated both vectors in the absence of digoxin
to determine the linear range of infection and chose an MOI of 0.1–0.2 (S1A Fig). Then we
infected Jurkat cells in the presence of digoxin (S1B Fig). In agreement with our previous
results, the N74D vector was less sensitive to digoxin relative to WT (S1B Fig). Hence the selec-
tive response to digoxin was independent of the fluorescent marker. We sought to confirm
digoxin selectivity using a replication competent virus. To this end, a titration was performed
on the luciferase Jurkat reporter cell line (1G5 cells) [31] using HIV-1 NL4.3 WT or N74D,
which showed that WT NL4.3 replicated marginally better than NL4.3 N74D (S1C Fig). Next,
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Fig 1. Digoxin inhibits HIV-1 infection more potently than N74D virus. (A) Schematic depiction of the high
through put screen; WT HIV-1 vector expresses GFP and N74D mutant HIV-1 vector expresses mCherry. Jurkat cells
are co-infected with both viruses and a library of small compounds is screened in 384 well plates. Cells are analysed
by dual-colour flow cytometry. Left plot depicts a non-hit compound, middle plot depicts a selective hit and the right
plot depicts a non-selective hit. (B) Jurkat cells were co-infected with WT and N74D vectors at an MOI of 0.1 in the
presence of the indicated compounds and analysed 24h later. Representative dot plots from the FACS analysis for
control (DMSO only), digoxin (300nM) or raltegravir (100nM) treated cells. (C) 1G5 Jurkat luciferase indicator cells
were infected at the same MOI with NL4.3 WT or with NL4.3 N74D in the presence of the indicated concentrations of
digoxin. Luminescence was measured 48 hours after infection; data are representative of two experiments performed
in triplicate. Error bars represent SEM. (D, E) Memory CD4+ T-cells were stimulated via CD3/CD28 Abs for 3 days
and infected with VSV-G pseudotyped HIV-1 LAIΔenv WT (D) or N74D mutant (E), cells were cultured in media
containing IL-2 in the presence or absence of the indicated doses of digoxin for additional 40 hours. The percentage of
viable, infected (GFP+) cells was determined by flow cytometry. Bar graphs represent mean ± SD of 9 donors.
Friedman test p-values are indicated on the graphs: *, p<0.05.
https://doi.org/10.1371/journal.ppat.1006460.g001
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we tested the effect of digoxin by titrating the drug on 1G5 cells infected with either NL4.3 WT
or NL4.3 N74D and reading luciferase 48 hours post-infection, when cell toxicity and differ-
ences in replication between the two viruses were both minimal. In these conditions, WT
NL4.3 was less sensitive to digoxin than NL4.3 N74D (Fig 1C). We also tested the selectivity of
digoxin in primary memory CD4+ T-cells. PBMCs were obtained from 9 healthy donors,
memory T-cells (CD3+ CD4+ CD45RA-) were sorted by negative selection, stimulated using
CD3/CD28 Abs and infected at an MOI of 0.1 with a VSV-G pseudotyped single cycle HIV-1
LAI with a deletion in env and expressing GFP in place of nef (HIV-1 LAIΔenv) [1]. Thirty-six
hours post-infection, the percentage of GFP+ cells was measured by flow cytometry after gat-
ing for the live cell population. In the absence of digoxin, WT and N74D HIV-1 LAIΔenv
viruses showed similar infection levels (S1D Fig). In the presence of digoxin, WT HIV-1 was
inhibited more strongly than N74D at concentrations greater than 200 nM (Fig 1D and 1E), in
agreement with the results in Jurkat cells. Therefore, we concluded that the high-throughput
screen identified digoxin as a genuinely selective antiretroviral.
Identification of the digoxin target responsible for antiretroviral activity in
CD4+ T-cells
A previous report showed that the Na+/K+ ATPase is the main target of digoxin mediating the
antiretroviral effect in 293T cells [30]. However, digoxin has two known targets, the nuclear
hormone receptor RORγ/γt, (also known as RORC), which is expressed in a subset of CD4
+ T-cells and innate lymphoid cells [32,33] and the α1-subunit of the Na+/K+ ATPase, which is
ubiquitously expressed [34,35,36]. Therefore, in CD4+ T-cells, digoxin might have more than
one target responsible for its antiretroviral activity. The co-crystal structure of RORγ/γt bound
to digoxin showed that the sugar moiety of digoxin is critical for stabilizing the drug into the
ligand-binding pocket of RORγ/γt [37]. Thus digoxin derivatives lacking two or more sugar
moieties, such as digoxigenin or ouabain, will only bind to the Na+/K+ ATPase but not to
RORγ/γt [36,38]; conversely, the lactone ring of digoxin is important for high-affinity binding
to the Na+/K+ ATPase [34] hence modification of the lactone ring in 20,22-dihydrodigoxin-
21-23-diol (Dig(dhd)) substantially reduces its affinity for the Na+/K+ ATPase but not for
RORγ/γt [35,36]. We synthesized Dig(dhd) and tested it in infection assays in Jurkat cells
using HIV-1 LAIΔenv. At 36h post-infection, cells were analysed by flow cytometry; digoxin
showed the typical biphasic inhibitory curve, and at a concentration of 100 nM suppressed
WT HIV-1 infection without affecting cell viability (Fig 2A). Dig(dhd) phenocopied digoxin,
showing the same typical biphasic curve, however it showed a drastic drop in antiretroviral
potency (Fig 2B).
This indicated that, in CD4+ T-cells, the main target of digoxin mediating the potent anti-
retroviral activity was the Na+/K+ ATPase. To further test this point, we expressed in Jurkat
cells the murine Na+/K+ ATPase (mATPase), which is not susceptible to digoxin inhibition
[39]. Cells expressing the mATPase, or control Jurkat cells, were infected with HIV-1 LAIΔenv
in the presence of digoxin or ouabain. The antiretroviral activity of digoxin was drastically
lower in Jurkat cells expressing the mATPase (Fig 2C). In contrast, digoxin and ouabain
potently inhibited HIV-1 LAIΔenv infection in control cells (Fig 2C). These results established
that, similar to 293T-cells [30], the Na+/K+ ATPase was the main digoxin target in CD4+ T-
cells.
Targeting the Na+/K+ ATPase with digoxin did not impair HIV-1 reverse transcription
(S2B Fig), nuclear entry (S2C Fig) or integration (S2D Fig) but reduced viral mRNA levels
(S2E–S2G Fig), in agreement with previous reports [29,30]. Laird et al. showed that digoxin
inhibits expression from a HIV-1 plasmid DNA transfected into 293T cells [30], which
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suggests that HIV-1 integration may not be necessary. Transfection of Jurkat cells is extremely
inefficient hence to test if the selective phenotype of digoxin was maintained in the absence of
integration, we titrated digoxin in Jurkat cells pre-exposed to a high dose (20μM) of raltegravir
(a potent integration inhibitor [40]) and infected them with WT or N74D HIV-1 LAIΔenv
(S2H Fig). In these conditions, residual viral gene expression mostly comes from non-inte-
grated viral genomes, which are lost during prolonged passage in culture [41,42]. As expected,
in the presence of raltegravir, infection by both WT and N74D viruses was reduced at 48h
post-infection (S2H Fig) and was reduced much further 10 days post-infection (S2I Fig). This
suggested that GFP expression at 48h mostly came from non-integrated viral genomes. Nota-
bly, in the presence of raltegravir, digoxin appeared to be less potent (IC50 >300nM) and was
no longer selective (S2H Fig). This suggested that the selective phenotype of digoxin depends
on integration.
Digoxin represses gene pathways involved in cell metabolism and T-cell
activation
The identification of Na+/K+ ATPase as the digoxin target did not readily explain preferential
inhibition of WT over N74D virus. Digoxin inhibits viral gene expression (S2E–S2G Fig) and
[29,30]), yet the promoter/enhancer regions (LTR) of WT and N74D viruses were identical,
excluding that the selectivity could be mediated by a direct effect of the drug on the LTR.
HIV-1 WT has a greater preference to integrate within or near active genes than N74D
virus [7,23] and digoxin can trigger changes in cellular gene expression [43,44]. We therefore
hypothesized that if WT virus was more prone to integrate into genes whose expression was
perturbed by digoxin then the virus might become more susceptible to the drug. Conversely, if
the N74D virus were less prone to integrate into genes perturbed by digoxin then this virus
would be less susceptible to the drug. To test this hypothesis we carried out, in parallel, global
gene expression and integration site analysis on cells that were infected with WT or N74D
HIV-1 in the presence of digoxin or DMSO.
Fig 2. Na+/K+ ATPase is the digoxin target mediating antiretroviral activity in CD4+ T-cells. (A) Jurkat cells were
infected with VSV-G pseudotyped HIV-1 LAIΔenvGFP at an MOI of 0.1 in the presence of the indicated doses of digoxin
and analysed by flow cytometry 36 hours post-infection. The chemical structure of digoxin is shown at the top. (B) Same
as for panel (A) but cells were infected in the presence of Dig(dhd). Dig(dhd) chemical structure is shown at the top. In
panels A and B error bars indicate SD, N = 3 independent experiments. (C) Jurkat cells stably expressing the mouse
Na+/K+ ATPase (mATPase), or an empty vector (vector), were infected with HIV-1 LAIΔenvGFP at an MOI of 0.1 in the
presence of the indicated concentrations of cardiac glycosides digoxin or ouabain, both Na+/K+ ATPase antagonists.
The percentage of infected, GFP+ cells was determined by FACS 24h post-infection. Data are representative of 3
independent experiments.
https://doi.org/10.1371/journal.ppat.1006460.g002
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We conducted three independent experiments in Jurkat cells infected with WT or N74D
LAIΔenv, ensuring that infection levels were within the linear range (S1E Fig), and extracted
total RNA and DNA from each sample 36h post-infection (S3 Fig). The RNA was used for
RNAseq and the DNA was used to perform high-throughput integration site analysis. Total
RNA was prepared for sequencing following the Illumina TruSeq mRNA protocol and
sequenced on an Illumina Nextseq to yield an average of 15 million reads per sample. One
sample (DMSO WT experiment 1) did not pass the RNA quality control and could not be
sequenced. Following alignment and removal of PCR duplicates, normalized read counts were
analysed using GeneSpring. A total of 2,826 genes were found differentially regulated (2-fold
or more, p< 0.05) by digoxin (S2 File). Cluster analysis demonstrated a clear and significant
distinction between treated and untreated samples but no significant distinction between cells
infected with either WT or N74D viruses (S4 Fig).
Normalised RNA read counts were studied for gene pathway enrichment using Ingenuity
Pathway Analysis (IPA) (www.qiagen.com/ingenuity). To identify changes in gene expression
likely to be of biological relevance, we applied a cut-off fold change4 with a p-value of<0.05
(Mann Whitney test after Benjamini-Hochberg false discovery rate). Using this filter, we
found digoxin up-regulated 221 and down-regulated 336 genes that could be unequivocally
mapped (S2 File). Within the up-regulated gene group, IPA showed that the main biological
functions affected by digoxin, in terms of both number of participating genes and significance,
were transcription of RNA and DNA, chromatin remodelling, cell cycle progression and cell
death and survival (Fig 3A, 3B and S3 File). A prominent up-regulated network was AP-1,
including Jun, Fos and ATF3; Jun was one of the most up-regulated genes, increasing 60 fold
in digoxin-treated cells (S2 File). Such strong up-regulation of Jun may be related to a survival
response to stress induced by digoxin [45].
Within the down-regulated gene group, the main biological functions affected by digoxin
were metabolism, in particular of cholesterol, lipids and carbohydrates, antigen presentation,
T-cell signalling and activation of leukocytes (Fig 3C and 3D S4 File).
WT HIV-1 preferentially integrates within or near genes susceptible to
silencing by digoxin
To validate the hypothesis that the selectivity of digoxin occurs at the integration stage, we
examined the integration profile of single cycle WT and N74D HIV-1 LAIΔenv in digoxin-
treated and untreated Jurkat cells. We analysed integration site selection using a high-through-
put method we recently developed [46,47]. We obtained between 15,000 and 56,000 unique
proviral integration site (UIS), depending on the sample (S5A Fig and Dasaset 5). No signifi-
cant differences in the number of UIS were observed between control and digoxin-treated
samples (S5A Fig). This was in agreement with the Alu-LTR qPCR results, which demon-
strated that digoxin did not inhibit HIV-1 integration (S2C Fig). Furthermore, no clonal
expansion was detected (compare total clones to shear sites in S5A Fig) because infected cells
were examined 36 hours post-infection.
UIS were mapped to human genome reference hg19 (S5 File); a control was generated in
silico using 100,000 non-gap genomic positions chosen at random, which were processed in
the same way as the experimentally observed UIS. WT and N74D viruses integrated preferen-
tially within any gene, however WT virus favoured integration within any gene more strongly
than the N74D virus relative to the expected random distribution (baseline) (Fig 4A left panel
and S5B Fig). WT virus had a clear preference (2 fold above baseline) to integrate near any
gene (10 Kb from the transcriptional start site) whereas N74D virus did not (Fig 4A right
panel), in agreement with previous observations [7,23,25]. Digoxin reduced WT virus
A functional link between HIV-1 integration and T-cell activation
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integration near any gene and increased N74D virus integration near any gene (p< 0.001,
Fisher’s exact test) but this effect was quite small (Fig 4A). In these conditions, the orientation
of the provirus relative to the cellular gene transcriptional start site was unchanged (S5C Fig).
Thus digoxin caused modest, albeit selective, changes in the integration preference of HIV-1
WT and N74D virus. Nonetheless, irrespective of digoxin treatment, a significant gap
remained between WT and N74D virus integration preference, which warranted further
investigation.
To achieve greater specificity, we examined integration preference within or near genes
whose expression was changed (4 fold up- or down-regulated) by digoxin, according to our
RNAseq results (S2 File). For greater stringency, because of the observed bias of WT virus to
integrate near and within genes, an in silico control for random integration sites within or
near genes was generated, which was processed in the same way as the experimentally
observed data. Then the ratio between UIS within or near genes down regulated by digoxin
Fig 3. Digoxin perturbs expression of specific gene pathways. (A) IPA-generated diagram showing the 221 genes up-regulated by
digoxin and their networks. Continuous lines indicate direct and experimentally validated interactions between genes; dashed lines indicate
experimentally validated, indirect interactions. Circular arrows indicate self-activation. Genes that could not be assigned to a network are
shown in the right hand corner. (B) List of the main functionally annotated pathways identified by IPA on the basis of the 221 genes up-
regulated by digoxin. The p-value for each pathway is shown on the x-axis. The full dataset is available in S3 File. (C) IPA-generated
diagram showing the 336 genes down-regulated by digoxin, same as for panel (A). (D) List of the main functionally annotated pathways
identified by IPA on the basis of the 336 genes down-regulated by digoxin. The p-value for each pathway is shown on the x-axis. The full
dataset is available in S4 File.
https://doi.org/10.1371/journal.ppat.1006460.g003
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Fig 4. WT HIV-1 integrates more frequently within or near genes that are susceptible to down-regulation
by digoxin. Three separate aliquots of Jurkat cells were independently infected with single cycle VSV-G
pseudotyped HIV-1 LAIΔenv WT or N74D at an MOI of 0.2 in the presence of DMSO or 400nM digoxin. Thirty-six
hours later, DNA was extracted and integration sites were identified and quantified. Same analysis was carried
out for a dataset of random integration sites generated in silico, sampled from a gap-excluded reference of the
human genome (hg19). This matched random control is shown as a blue dashed baseline, pointed by an arrow.
(A) Plots for integration of HIV-1 WT and N74D within (left panel) or near (within 10kb of start site) (right panel)
known genes. (B) Plots for integration of WT and N74D virus within (left panel) or near (right panel) genes
susceptible to down-regulation by digoxin relative to their baseline bias to integrate within or near any gene. (C)
A functional link between HIV-1 integration and T-cell activation
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and all UIS within or near genes was calculated. Notably, WT virus integrated more often than
N74D virus within genes susceptible to down-regulation by digoxin (1.5 fold above baseline)
(Fig 4B left panel), and this effect was stronger (2.5 fold above baseline) near such genes (Fig
4B right panel), demonstrating selectivity. This difference between WT and N74D virus was
large enough to suggest biological relevance. Digoxin treatment had a small yet selective
impact on the integration preference of each virus (Fig 4B).
WT and N74D viruses also integrated more often than matched random control within or
near genes susceptible to up-regulation by digoxin (Fig 4C). Notably, however, in contrast to
the situation in the down-regulated genes, there was no WT/N74D selectivity for integration
within up-regulated genes, there was a modest selectivity for integration near up-regulated
genes and digoxin treatment enhanced the integration preference of each virus (Fig 4C). Thus
integration within or near genes susceptible to up-regulation by digoxin was unlikely to
explain the selective phenotype.
In light of these results, we next examined integration within or near genes belonging to the
two main gene pathways down-regulated by digoxin: T-cell activation and cell metabolism,
which are intimately related both to each other and to HIV-1 infection [48,49,50,51]. Based on
IPA, we identified 59 and 73 genes involved in T-cell activation and cell metabolism, respec-
tively (S4 File). In the absence of digoxin, integration of WT virus within T-cell activation
genes was1.8-fold above baseline, and approximately 4-fold above baseline near such genes
(Fig 5A). The N74D virus integration preference within this gene group was similar to baseline
whereas integration near these genes was2-fold above baseline (Fig 5A). Digoxin increased
N74D virus integration frequency within or near the T-cell activation genes although this did
not reach statistical significance, presumably due to the lower number of integration sites that
could be analysed (Fig 5A). Digoxin had little or no effect on WT virus integration frequency
within or near T-cell activation genes, which remained much higher than random, irrespective
of the drug (Fig 5A). To explain this observation, we speculate that WT virus integration
within or near this gene group is faster than the effect of digoxin on their expression levels. A
similar trend in WT and N74D virus integration preference was found for the group of genes
related to cell metabolism (Fig 5B). Therefore, although a total of only 132 genes were analysed
in the T-cell activation and cell metabolism pathways, WT virus integration within or near
these genes was disproportionally frequent both in absolute terms and relative to the N74D
virus.
As a control for this analysis, we also examined integration preference in the hereditary and
developmental disorder gene network (66 genes), also identified by IPA among the genes
down-regulated by digoxin (S6 File). Although there was integration preference above baseline
in this group of genes, it was not as pronounced as for T-cell activation or metabolism genes
and there was no difference between WT and N74D viruses (Fig 5C). This suggested that WT
virus has some degree of specific integration targeting within certain groups of genes.
To test this notion further, we looked for integration hotspots of WT or N74D viruses in
our samples. Hotspots were defined as genes having more than 5 UIS in at least two out of
three experiments. We detected 24 hotspots in total with integration frequencies ranging from
Same as (B) but plots show integration within (left panel) or near (right panel) genes susceptible to up-regulation
by digoxin. Each bar shows an aggregate result from all three replicates, with the range of results for the individual
replicates shown by the whiskers. Black asterisks above bar graphs denote statistical significance between
control (DMSO) and digoxin-treated samples. Blue asterisks just above the bar graphs denote statistical
significance in the samples relative to baseline (same analysis carried on the in silico sites) and was assessed
using the Fisher’s exact test with Bonferroni’s correction for multiple comparisons (* < 0.05, ** < 0.01, *** <
0.001).
https://doi.org/10.1371/journal.ppat.1006460.g004
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Fig 5. WT HIV-1 integrates more frequently than N74D within or near genes involved in T-cell activation and
cell metabolism. UIS, as well as matched random controls, were obtained as described in Fig 4 and annotated for
integration within or near (within 10kb of transcript start site of) known genes, as well as genes susceptible to down-
regulation by digoxin belonging to specific IPA pathways: T-cell activation, cell metabolism and hereditary disorder.
Plots for integration of WT and N74D virus within (left panel) or near (right panel) T-cell activation genes (A), cell
metabolism genes (B) and hereditary disorder genes (C). Each bar denotes the proportion of integration sites found
within (left panel) or near (right panel) genes of the particular pathway within all integration sites within or near genes.
The same analysis was carried out in the matched random control sites, shown as the blue dashed baseline, pointed
by an arrow. Each bar shows an aggregate result from all three replicates, with the range of results for the individual
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11 to 74 UIS (Fig 6). Remarkably, WT virus had 23 hotspots and N74D virus had only one hot-
spot (in the RAG2 gene) (Fig 6). We annotated the hotspots using IPA and Genecards and
found that 13 of them were in genes belonging to the cell metabolism, T-cell activation and
antigen presentation pathways (highlighted in red in Fig 6). This result supported the notion
that WT selectively integrates within specific gene pathways and that this selectivity is lost for
the N74D virus.
Recent studies showed that HIV-1 tends to integrate more frequently within highly
expressed genes [23,52] hence the selective integration preference of WT virus might be influ-
enced by expression levels of target genes. We compared expression of the genes susceptible to
up- or down-regulation by digoxin with that of all genes (Fig 7). Genes unaffected by digoxin
showed a biphasic distribution with approximately 30% of them little or not expressed and
approximately 25% of them highly expressed (Fig 7A). Genes susceptible to down-regulation
by digoxin were the most highly expressed, followed by genes susceptible to up-regulation by
the drug. Furthermore, the median level of expression was significantly higher for genes sus-
ceptible to down-regulation compared to the other two groups (Fig 7B). We correlated gene
expression levels with frequency of integration for WT and N74D viruses. There was a clear
correlation between gene expression and integration frequency for both WT and N74D
viruses, however we detected selectivity in the most highly expressed gene group: WT virus
integrated into such genes more frequently than N74D virus (Fig 7C), which is in agreement
with a recent report [23]. Thus WT virus integrates more frequently than N74D virus within
or near the most highly expressed genes; genes susceptible to down regulation by digoxin are
amongst the most highly expressed hence WT virus integrates into such genes more frequently
than N74D virus. These results support the link between differential sensitivity to digoxin of
WT and N74D viruses and their different integration preference.
Inhibition of CD40L selectively affects WT HIV-1 infection
We sought to test further the biological relevance of this link. Within the T-cell activation
pathway identified by IPA, the CD38 and CD40L signalling networks were prominent and
showed some degree of overlap (Fig 8A and S6A Fig). Upon digoxin treatment, RNAseq
showed that CD40L down-regulation was 8-fold and CD38 down-regulation was 4-fold (S2
File). T-cells express CD38 and CD40L upon activation and proliferation [53,54] and lower
levels of these markers in digoxin-treated cells suggested that the drug might induce a more
quiescent phenotype. Given the profound impact of T-cell activation on HIV-1 gene expres-
sion [48] and the high frequency of HIV-1 integration within or near genes of this network, we
chose the CD40L pathway for further analysis. We isolated primary CD4+ memory T-cells
from 3 healthy donors, stimulated them with anti-CD3/CD28 beads, treated them with digoxin
for 24h and analysed cells by flow cytometry for surface expression of CD40L. Digoxin consis-
tently reduced levels of CD40L, both in terms of number of cells expressing the marker and
their mean fluorescent intensity (MFI) (Fig 8C and 8D), validating the RNAseq data. Digoxin
also down-regulated CD38 expression in primary CD4+ T-cells (S6B and S6C Fig)
We then blocked CD40L with a neutralizing antibody in acutely infected cells. Jurkat cells,
which express functional CD40L [55,56], were infected with HIV-1 LAIΔenv WT or N74D at
an MOI ranging from 0.05 to 0.2 in the presence of different doses of an anti-CD40L neutraliz-
ing antibody. Cells were analysed 36-48h post-infection; the neutralizing antibody reduced
replicates shown by the whiskers. Statistical significance refers to UIS in sample relative to the baseline bias and was
assessed using the Fisher’s exact test with Bonferroni’s correction for multiple comparisons (* < 0.05, ** < 0.01, ***
< 0.001). No significant difference was found between control (DMSO) and digoxin-treated samples in these groups.
https://doi.org/10.1371/journal.ppat.1006460.g005
A functional link between HIV-1 integration and T-cell activation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006460 July 20, 2017 12 / 28
WT HIV-1 infection in a dose-dependent way, with maximal inhibition at 250ng/ml (Fig 8E).
Remarkably, the N74D virus was unaffected by the antibody (Fig 8E). Thus inhibition of
CD40L by the anti-CD40L neutralizing antibody had a selective effect on HIV-1 infection,
mimicking digoxin. Overall our results support the notion that the virus integration prefer-
ence, combined with targeted gene repression, had functional consequences.
Discussion
Using a novel screening approach, we found that digoxin inhibited WT HIV-1 more potently
than the N74D mutant virus. We confirmed previous studies showing that digoxin represses
HIV-1 gene expression, yet WT and N74D viruses share an identical promoter. We found that
digoxin repressed preferentially cellular genes involved in T-cell activation and cell metabo-
lism. We subsequently found that WT HIV-1 integrated within or near those genes more fre-
quently than N74D HIV-1. This led us to hypothesize that the integration preference of WT
virus makes it more susceptible to digoxin than N74D virus because WT virus would be
repressed in tandem with cellular gene expression. To our knowledge, our results for the first
time demonstrate a functional connection between acute changes in T-cell activation or
Fig 6. Analysis of integration frequencies shows enrichment of integration hotspots within genes involved in T-cell activation
and cell metabolism. Global integration frequencies were calculated in each replicate experiment. An integration hotspot had > 5
independent integration events in at least two replicate experiments. Genes highlighted in red are involved in T-cell activation or cell
metabolism as determined by IPA and Genecards annotation.
https://doi.org/10.1371/journal.ppat.1006460.g006
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metabolism and HIV-1 integration site selection. We suggest that this connection has impor-
tant biological significance.
It was previously reported that digoxin has potent antiretroviral activity [29,30] and that the
drug specifically impairs the generation of single-spliced viral mRNAs and production of Rev
Fig 7. Genes sensitive to digoxin are highly expressed. (A) The percentage of genes expressed at low,
intermediate or high levels were plotted for each group: all genes (n = 20100), genes up-regulated by digoxin
(n = 221) and genes down-regulated by digoxin (n = 336). Normalized expression values (RPKM) for each
gene in each dataset were binned according to expression intensity in the digoxin-negative samples (x-axis).
For each expression bin, the percentage of genes present in that bin is shown. (B) The distribution in
normalized expression (in the absence of digoxin) between upregulated, downregulated or all genes. (C)
Correlation of integration frequency with measured levels of gene expression. Normalized expression values
(RPKM) for each gene in each dataset were binned according to expression intensity (x-axis). Y-axis indicates
UIS in a gene of a particular expression bin (normalized by gene length) over the proportion of random sites in
genes in the same bin. Each circle on the graph is the median of three experiments, and the whiskers indicate
the range of values observed over the three experiments.
https://doi.org/10.1371/journal.ppat.1006460.g007
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Fig 8. Inhibition of CD40L selectively affects WT HIV-1. (A) IPA diagram highlighting genes in the CD40L
pathway that are susceptible to down-regulation by digoxin. HIV-1 WT preferentially integrates within or near these
genes. Continuous lines indicate direct and experimentally validated interactions between genes; dashed lines
indicate experimentally validated, indirect interactions. (B-D) Purified memory CD4+ T-cells were stimulated via
CD3/CD28 Abs, cultured for 3 days and exposed to the indicated concentrations of digoxin for 24h. Cells were
labeled with anti-CD40L FITC-conjugated antibodies, stained for cell viability and analyzed by flow cytometry. (B)
Gating strategy to select single, live CD4+ T-cells. (C) Representative plot showing the percentage of memory CD4
+ T-cells expressing CD40L on their surface in the presence of the indicated concentrations of digoxin (y-axis). (D)
The percentage of CD40L positive cells and the MFI were quantified by flow cytometry. Bar graphs represent
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[29]. In our screen, we used HIV-1 vectors that express GFP from an unspliced mRNA yet an
inhibitory effect of digoxin was still detected. Furthermore, our WT and N74D HIV-1 con-
structs were identical except for the point mutation in CA. Thus it is unlikely that splicing
defects of the viral mRNA are the main cause of the digoxin phenotype observed in the present
study. Accordingly, Wong et al. also observed that HIV-1 mRNA splicing defects, or Rev inhi-
bition, were insufficient to fully explain the potent antiretroviral activity of digoxin [29]. We
note, however, that the IC50 of digoxin reported by Wong et al. [29] is lower than the IC50
reported in the present study. This indicates that our single round infection assays might
bypass the viral gene expression block caused by aberrant splicing. Indeed, in our LAIΔenv
HIV-1 constructs, Nef is replaced by GFP, which is expressed from a multiply spliced viral
RNA independent of Rev for export [1]. Laird et al. [30] found that digoxin can also inhibit
expression from an HIV-1 plasmid transfected in 293T cells, suggesting that integration may
not be necessary. Because transfection of Jurkat cells is extremely inefficient, we infected cells
in the presence of digoxin and a high dose of raltergavir to inhibit integration. In these condi-
tions, GFP expression mostly comes from non-integrated viral genomes, which are lost during
prolonged passage in culture [41,42]. Raltegravir produced two effects: it increased digoxin
IC50 above 300nM and abrogated digoxin selectivity. These results suggested that integrated
proviruses are more susceptible to digoxin than non-integrated viral genomes and that the
selectivity of digoxin depends on integration. This is unsurprising because integrated provi-
ruses are chromatinized and become susceptible to more complex regulatory mechanisms
than non-integrated HIV-1 genomes [48,57,58].
In any case, our present study focuses on the selective activity of digoxin, which is novel
and was discovered because of the unique design of our screen. By concentrating on the mech-
anism that underpins digoxin selectivity, we have unmasked a link between CD4 T-cell activa-
tion and HIV-1 integration of broad significance.
Because WT and N74D viruses were identical, except for the point mutation in CA, the
selective activity of digoxin was unlikely to have a direct explanation. Instead, our results sug-
gest that selectivity may result from a combination of factors. Firstly, in normal conditions,
WT and N74D viruses have different integration site distributions and we found that WT
virus integrates more frequently than N74D virus within or near genes implicated in T-cell
activation and cell metabolism, which are highly expressed in activated CD4+ T-cells. Sec-
ondly, as it happens, we found that digoxin inhibits specific gene pathways, mostly involved in
cell metabolism and T-cell activation. The simplest interpretation linking these results together
is that WT virus, by virtue of its integration preference, is intrinsically more susceptible than
N74D virus to transcriptional perturbations of certain genes (S7 Fig).
This interpretation is supported by the differential effect of blocking CD40L on WT and
N74D viruses, which mimicked digoxin. The selective effect of CD40L blockage would be diffi-
cult to explain with a direct effect on the viral promoter. Instead, the results suggest that a pro-
portion of the GFP signal in cells infected with WT virus is accounted for by proviruses
susceptible to CD40L blockage. It is unclear if proviruses integrated within or near genes
belonging to specific pathways such as cell metabolism and T-cell activation are more highly
expressed, or more likely to be expressed in T-cells. Our results hint at the possibility that cer-
tain networks of genes, in which HIV-1 preferentially integrates, may contribute
mean ± SD of 3 donors. Friedman test p-values are indicated on the graphs: *, p<0.05; ** p<0.01. (E) Jurkat cells
were infected with HIV-1 LAIΔenv GFP WT or N74D at MOIs of 0.05–0.2 in the presence of the indicated
concentrations of the anti-CD40L neutralizing antibody and analysed by flow cytometry 48h after infection to
measure the percentage of GFP+ cells. Dot plots showing the results of five independent experiments. Unpaired,
two-tailed t-test p-values are indicated on the graphs: *, p<0.05; **, p<0.01.
https://doi.org/10.1371/journal.ppat.1006460.g008
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disproportionally to viral gene expression at the early stages post-infection, although further
work will be necessary to address this issue. It would also be interesting to investigate if the
selective digoxin effect on HIV-1 gene expression is recapitulated in other cell types. We spec-
ulate that the selective phenotype might be smaller because genes pathways for T-cell signalling
would not be highly expressed, although presumably gene pathways for metabolic activity
would be, depending on the cell type.
Our interpretation to explain the selectivity of digoxin requires that HIV-1 gene expression
should be influenced by the status of the surrounding chromatin, whereby locally induced
chromatin repression also affects the provirus. In support of this notion, it has been shown
that the genomic site of provirus integration influences HIV-1 transcription before sufficient
amounts of viral protein Tat are made (the so-called Tat-independent phase) [59]. Further-
more, chromatin repression near or at the newly integrated provirus prevents the remodelling
at the LTR DNA necessary for viral transcription [60,61,62], until Tat promotes chromatin
activation [63].
It is presently unclear how CA should influence the activity of a compound acting on viral
gene expression. Nonetheless, because the selective phenotype of digoxin depends at least in
part on integration site selection, it should be influenced by specific interactions between CA
and host factors that target HIV-1 integration. One candidate is CPSF6, which was recently
reported to direct HIV-1 integration near highly expressed, intron-rich and highly spliced
genes [23]. Initial experiments using 293T CPSF6 KO cells [23] did not show a major role for
CPSF6 in mediating the selective phenotype of digoxin, clearly though CD4+ T-cells would be
more relevant targets. We have been unable so far to generate CPSF6 knock down or KO CD4
+ T-cells. It is also possible that additional host factors, such as LEDGF/p75, cooperate with
CPSF6 to direct HIV-1 integration into genes implicated in T-cell activation and metabolism.
The degree of proximity of WT and N74D integration sites to heterochromatin located at the
nuclear periphery may also be important to determine susceptibility to digoxin [64,65]. These
lines of investigation are worth pursuing in the future.
It is well established that HIV-1 preferentially integrates within transcribed, intron-rich
and highly spliced genes embedded with histone marks of active chromatin [21,22,23,24,52].
However, the functional significance of this targeting has remained rather elusive. By acutely
perturbing cellular gene expression and comparing WT to N74D mutant viruses, we have
been able to show that, in CD4+ T-cells, WT HIV-1 has a significant greater preference to inte-
grate into or near genes implicated in T-cell activation and cell metabolism than N74D virus,
which has functional consequences at least in the early stages post-infection. Our analysis is
limited to a CD4+ T-cell line. Nonetheless, the overall pattern of HIV-1 integration site selec-
tion is conserved across many different cell lines and primary cells [66,67,68,69,70] and we
detected the selective effect of digoxin on HIV-1 infection in primary memory CD4+ T-cells
too. It is therefore likely that our observation is true in many cell types, including primary
cells.
We suggest that a functional link connecting HIV-1 integration preference to T-cell activa-
tion and metabolism has broad significance. Activation of naive T-cells, their differentiation
into quiescent memory cells and the activation of memory cells are rapid events that require
profound physiological changes involving specific T-cell signalling pathways and metabolic
adaptation [49,50,71]. The metabolism of CD4+ T-cells changes dramatically on entering or
exiting quiescence: upon activation, T-cells adopt an anabolic metabolism, increase glycolysis
and fatty acid oxidation whereas quiescent cells rely mainly on oxidative phosphorylation [71].
Because the site of provirus integration influences early HIV-1 transcription [59], our results
suggest that the probability of HIV-1 integration within or near genes involved in T-cell activa-
tion and cell metabolism may favour rapid viral gene expression and replication in activated
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CD4+ T-cells. Conversely, if a CD4+ T-cell enters quiescence shortly after infection, proviruses
within or near T-cell activation and metabolic genes should be more likely to become silenced
in tandem with the cellular genes due to changes in the local chromatin. Therefore the cell fate
(quiescent/memory or activated/effector) would be linked to the virus fate (silenced or active)
for a short time post-infection, before Tat overrides local chromatin constraints to HIV-1 gene
expression [72]. In this scenario, in cooperation with transcription factors expressed in CD4
+ T-cells that activate the viral promoter [48], integration site selection would be an additional
layer regulating HIV-1 gene expression in a cell-state dependent manner. Consistent with this
idea, it was recently shown that retargeting HIV-1 integration in CD4+ T-cells away from
actively transcribed genes by LEDGF/p75 antagonists reduces the fraction HIV-1 that can later
be reactivated from latency [73].
Materials and methods
Ethics statement
Blood samples were obtained from healthy volunteers after written informed consent accord-
ing to the approved protocol of the UCL Ethics Committee ref. 2649/001. The study was
approved by the joint University College London / University College Hospitals National
Health Service Trust Human Research Ethics Committee and written informed consent was
obtained. For experiments shown in Fig 1 and Fig 8, peripheral blood mononuclear cells
(PBMCs) were collected at the McGill University Health Centre, Montreal, Quebec, Canada
from healthy donors, in compliance with the principles included in the Declaration of Helsinki
and received approval from the Institutional Review Board of the McGill University Health
Centre and CHUM-Research Centre. All subjects signed a written informed consent for their
study participation.
Chemical compounds
Digoxin, ouabain, coumermycin-A1, and nevirapine were obtained from Sigma-Aldrich, Dor-
set, UK; raltegravir was obtained from Santa Cruz Biotechnology, Dallas, TX, USA, digitoxin
was obtained from MP Biomedicals, UK, digoxigenin from Fluka, Dorset, UK. 20,22-dihydro-
digoxin-21-23-diol (DHD) was synthesized as previously described [36].
Cell lines and viruses
HeLa and 293T cells (European Collection of Authenticated Cell Culture [ECACC] Public
Health England, UK) were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco
Labs, Paisley, UK) supplemented with 10% foetal calf serum (FCS) (Helena Bioscience, New-
castle, UK) and 2 mM glutamine (Gibco Labs) at 37˚C in 5% CO2. Jurkat E6.1 (ECACC) and
Jurkat indicator line 1G5 containing the firefly luciferase gene driven by the HIV LTR (AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: from Dr. Estuardo
Aguilar-Cordova and Dr. John Belmont) were grown in RPMI medium (Gibco Labs) supple-
mented with 10% FCS at 37˚C in 10% CO2. Viral stocks were prepared by transfection of 293T
cells as described previously [15,74] using pHIV LAIΔenv (gift of Michael Emerman, Fred
Hutchinson Cancer Research Centre, Seattle, USA) [1], HIV-1GFP vectors (gift of Adrian
Trasher, Institute of Child Health, UCL, UK) and NLENG1-IRES YU-2 (HIV-1 modified to
contain GFP and Nef separated by an IRES–[75] (gift of David N. Levy, New York University,
USA). HIV isolates NL4.3 (Centre for AIDS Reagents, Health protection Agency, UK), YU-2
and BaL (NIH AIDS Reagent Program) were produced by Fugene transfection into 293T cells
and supernatant containing viral particles was collected 48h post-transfection as described
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[15,16]. Reverse transcriptase (RT) activity was measured by the Lenti-RT™ Activity Assay
(Cavidi Tech, Uppsala, Sweden) following the manufacturer’s instructions. For infections,
13ml of 1G5 cells (~0.9x106/ml) were mixed with 2ml NL4-3 (WT or N74D). The mix was dis-
pensed robotically, 45μl/well onto 384-plates preloaded with drug dilutions. Samples were ana-
lysed 48 h post-infection using the BrightGlo assay according to the manufacturer’s
instructions in a Pherastar plate reader. To generate Jurkat cells stably expressing the mouse
Na+/K+ ATPase, mus musculus Na+/K+ transporting alpha 1 polypeptide cDNA (Origene
MC204215, Rockville, MD, USA) was cloned into the MLV-based retroviral vector pMIG Zeo
[76] (gift of Jeremy Luban, UMASS, USA). Virus was produced in 293T cells as described and
used to transduce Jurkat cells, which were selected in the presence of 1μM ouabain for 10 days.
Primary cells
Peripheral blood mononuclear cells (PBMCs) were isolated from leukapheresis of HIV-1 nega-
tive subjects by Ficoll-Paque (Amersham Biosciences) gradient density centrifugation. Mem-
ory CD4+ T-cells were sorted from PBMCs by negative selection using magnetic beads (CD4
+ T-cell Isolation Kit or Memory CD4+ T-cell Isolation Kit, Miltenyi, Bergisch Gladbach, Ger-
many) with a purity >95%, as determined by staining with CD3-Pacific blue (UCHT1),
CD4-Alexa Fluor 700 (RPA-T4), CD45RA-allophycocyanin/Cy7 (HI100) (BD Pharmingen,
San Diego, CA), CD8-FITC (BW135/80) (Miltenyi) and FACS analysis [77]. Purified memory
CD4+ T-cells were stimulated via CD3/CD28 (immobilized CD3 Abs and soluble CD28 Abs,
NA/LE, 1 μg/ml, BD Pharmingen, Oxford, UK) and cultured in RPMI1640 media containing
10% FBS, 1% penicillin/streptomycin (PS) for 3 days. Macrophages were isolated by standard
Ficoll-Hypaque density centrifugation and incubated at a density of 5x104/well in a volume of
100μL in 96 well plates for 72h in the presence of 20ng/ml of GM-CSF (BD Biosciences) before
media change and infection at day 5. PBMCs were transferred into RPMI medium containing
10% FCS and activated with 2μg/mL phytoemagglutinin (PHA) (Sigma Aldrich) for 48h,
media was changed and cells were infected and grown for three days in the presence of 10U/
mL IL-2 (R&D Systems, Wiesbaden, Germany). Cells were exposed to VSV-G pseudotyped
HIV-1 LAIΔenv WT (25 ng CAp24/106 cells) or mutant N74D (50 ng CAp24/106 cells), for 3
hours at 37˚C. Unbound virus was removed by extensive washing and cells were cultured in
media containing IL-2 (5 ng/ml) in the presence or absence of digoxin (10, 50, 100, 200, and
300 nM) for 40 hours. Cells were harvested and stained with FITC-conjugated CD38 Abs (BD
Biosciences), as previously described [78]. A cell viability “Vivid staining” kit (Molecular
Probes LIVE/DEAD Fixable Dead Cell Stain Kits, Invitrogen, Thermo-Fisher, Waltham, MA,
USA) was used to exclude dead cells from the analysis. The expression of CD38 on viable cells
was analyzed using the BD LSRII cytometer (BD). Expression levels of CD154/CD40L were
measured as previously described [79] [80]. Briefly, purified memory CD4+ T-cells were stim-
ulated via CD3/CD28 and cultured for 3 days. After 24 hours with digoxin treatment, cells
were exposed to 2 μM of monensin (Sigma) and 10 μL/wells of FITC-conjugated CD40L Abs
(BD Biosciences) for 16 hours at 37˚C. Cells were then harvested, stained for cell viability and
analyzed by flow cytometry.
High throughput screening
HTS was performed in 384 well plates (white flat bottom from Greiner) using a Cybio Cybi-
Well Vario liquid handling robot with a 384 head plus CyBi-Drop and V&P 384 pin tool to
accurately transfer 100 nL of compounds from the master plates. The entire system is enclosed
in a special cabinet located in a category 3 laboratory. WT and N74D viruses were pre-mixed
at 4˚C at a ratio to have approximately 10% of cells infected with each virus. The virus mix was
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added to the cells in batch, incubating at 4˚C with gentle mixing. 5x104 cells/well in 50μl were
plated in 384-well plates and 100 nL compound were added to each well (at 1μM final concen-
tration). After 36 hours incubation at 37˚C, cells were fixed and analyzed by HTS flow cytome-
try using a BD LSR II automated to 384-well plates. Data were analyzed using FlowJo software,
which also provided information on cell viability. A Z’ score was calculated for each plate. Hit
compounds detected in plates with a Z’ score between 0.5 and 1 were considered significant.
Hits (h) were defined as follows: h (average % GFP+ cells of control–SD)/2 in the absence of
mCherry inhibition.
RNA sequencing
Three flasks containing Jurkat cells (30 mls at 0.8x106/ml) were independently infected with
VSV-G pseudotyped LAIΔenv WT or N74D at an MOI of 0.2 in the presence of DMSO or
400nM digoxin. An aliquot of the cells was analysed by FACS 36 hours post-infection and
nucleic acids were extracted from the remaining cells using Qiagen RNAeasy Blood & Tissue
kit following the manufacturer’s instructions. 250 ng of total RNA was prepared for sequenc-
ing following the Illumina TruSeq mRNA (unstranded) protocol, multiplexed, and sequenced
(V2 High Output kit, 43bp PE) on an Illumina Nextseq to yield an average of> 15 million
reads per sample. Data was de-multiplexed using bcl2fastq v 2.16. Read QC reports were gen-
erated in Illumina Basespace. Fastq files passing read QC were analysed on the UCL Genomics
cluster using an in house pipeline (Python/R). Briefly, sequencing reads were aligned to an
appropriate reference genome using TopHat v2.0.13 and PCR duplicates removed using
Picard tools (v1.100). GTF files describing genes features were obtained from the Ensembl
website (http://www.ensembl.org/info/data/ftp/index.html) and read count data for each
genomic feature were obtained using the python scripts provided as part of the Deseq2 pack-
age. Read count data was subsequently normalized and differential expression computed using
Deseq2. Normalized read counts (normalized using the Deseq2 library size procedure) was
visualised in Genespring 12.0 (Agilent) and analysed using Ingenuity Pathway Analysis. The
set of scripts used is freely available at https://github.com/plagnollab/RNASeq_pipeline.
Sequence data can be downloaded from NCBI SRA accession PRJNA321856.
Integration site analysis
DNA was extracted using Qiagen DNeasy Blood & Tissue kit following the manufacturer’s
instructions. Integration sites were identified and quantified in DNA samples as detailed previ-
ously [47] using the following HIV-specific PCR forward primers: HIVB3 5’-GCTTGCC
TTGAGTGCTTCAAGTAGTGTG-3’, HIVP5B5 5’-AATGATACGGCGACCACCGAGAT
CTACACGTGCCCGTCTGTTGTGTGACTCTGG-3’ and HIV-specific sequencing primer
5’-ATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTC-3’. Prepared sequencing librar-
ies were sequenced on a rapid run of the Illumina HiSeq platform at the Medical Research
Council Clinical Sciences Centre Genomics laboratory at Hammersmith Hospital, London,
UK. 50 base paired-end reads were aligned to the human genome (hg19) using the eland_pair
implementation of CASAVA. In silico sites were derived by random sampling of 100,000 sites
from the gap-excluded reference of the human genome (hg19). Genomic positions of genes
were retrieved from UCSC table browser [81] or published data. Specific gene lists (i.e. genes
downregulated by digoxin) were compiled by deriving a non-repetitive list of genes from Inge-
nuity pathway analysis output and matched against UCSC gene tables to derive genomic coor-
dinates. Integration sites were annotated with these genomic positions using the R
Bioconductor package hiAnnotator [82]. Statistical analysis was carried out using R version
2.15.2 (http://www.R-project.org/).
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qPCR
For Taqman qPCR, approximately 1x106 cells were washed twice in PBS and total DNA was
extracted with the Qiamp DNA Minikit (Qiagen, Manchester, UK). Quantitative PCR reac-
tions were carried out as previously described [74] using 0.3pmol each primer and 0.15 pmol
of the probe in 25 μL volume containing 100-300ng total DNA using an ABI Prism 7000
Sequence Detection System (SDS). For amplification of (-) DNA strand (GFP), primers used
were forward: CAACAGCCACAACGTCTATATCAT, reverse ATGTTGTGGCGG ATCT
TGAAG and probe 5’-FAM-CCG ACA AGC AGA AGA ACG GCA TCA A-3’TAMRA. For
amplification of 2LTR circular DNA, the same conditions were used with primers
2LTRqPCR-F: 5’-AACTAGAGATCCCTCAGACCCTTTT-3’ and 2LTRqPCR-RC: 5’-CTTG
TCTTCGTTGGGAGTGAATT-3’ and 2LTR probe 5’-FAM-CTAGAGTTTTCCACACT
GAC-0-TAMRA-3’. Standards were prepared by PCR amplification of DNA from acutely
infected cells with primers 2LTRF 5’-GCCTCAATAAAGCTTGCCTGG-3’ and 2LTRRC 5’-
TCCCAGGCTCAGATCTGGTCTAAC-3’. The amplification product was cloned into TOPO
vector, amplified and confirmed by sequencing [16]. Alu-LTR Taqman qPCR was carried out
as previously described [16] using primers ALU-forward, AAC TAG GGA ACC CAC TGC
TTA AG and LTR1-reverse, TGC TGG GAT TAC AGG CGT GAG (for first round amplifica-
tion) and ALU-forward AAC TAG GGA ACC CAC TGC TTA AG, LTR2-reverse, TGC TAG
AGA TTT TCC ACA CTG ACT, ALU-probe, FAMRA–TAG TGT GTG CCC GTC TGT TGT
GTG AC–TAM (for second round Taqman qPCR).
CD40L assay
Jurkat cells were plated in round-bottom 96 well plates (105/well/100μL) and infected with
VSV-G pseudotyped LAI-GFPΔenv in the presence of serial dilutions of anti-hCD40L-Ig anti-
body (InvivoGen MAbg-h401-3). Cells were analysed by FACS 48h post-infection.
Supporting information
S1 Fig. Linearity of the infection assays. (A) Jurkat cells were infected with different doses of
VSV-G pseudotyped HIV-1 vectors WT or N74D and analyzed by flow cytometry 48 hours
later. WT vector expressed mCherry (CHE) and the N74D vector expressed GFP. (B) Jurkat
cells infected with WT or N74D HIV-1 vectors were exposed to the indicated concentrations
of digoxin and analysed by flow cytometry 48 hours later. (C) 1G5 Jurkat reporter cells were
infected with HIV-1 NL4.3 WT or N74D and the amount of luciferase assessed at the indicated
time points. (D) Primary memory CD4+ T cells from 9 donors were infected with HIV-1
LAIΔenv WT or N74D in the absence of digoxin and infection levels (GFP+ cells) measured
48 hours post-infection. Lines connect the same donor. (E) Jurkat cells were infected with dif-
ferent concentrations of HIV-1 LAIΔenv WT or N74D and analysed by flow cytometry 48
hours post-infection. Two separate viral stocks were tested.
(JPG)
S2 Fig. Digoxin inhibits HIV-1 gene expression in CD4+ T-cells. (A) Jurkat cells were
infected with VSV-G pseudotyped WT HIV-1 LAIΔenv expressing GFP (LAIGFP) in the pres-
ence of the indicated doses of digoxin and cells were analyzed by flow cytometry 48 hours
post-infection. Digoxin inhibited HIV-1 infection with an IC50 160nM. (B-D) Jurkat cells
were infected as above in the presence of digoxin (400 nM), nevirapine (50 nM) or DMSO and
DNA was extracted from the cells 24 or 48 hours after infection. The amount of total viral
DNA (B), 2LTR circular DNA (C) and integrated viral DNA (D) was quantified by TaqMan
qPCR. Mean values ± SD are shown, N = 3. (E-F) Jurkat cells were infected as before and 24h -
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36h post-infection they were treated with 400nM digoxin for 24h before analysis by flow
cytometry to determine the mean fluorescence intensity (MFI) (E) and the percentage of
infected (GFP+) cells (F). (G) Jurkat cells were infected for 24h as described in (B), treated
with the indicated doses of digoxin and the amount of HIV-1 pol mRNA quantified by RT-
qPCR 36h later. Mean values ± SD are shown, N = 3. (H) Jurkat cells infected with LAIGFP
with or without 20μM raltegravir (RALT) and the indicated concentrations of digoxin. Cells
were analysed by flow cytometry 48h post-infection to measure the percentage of GFP+ cells
within the live cell population. Mean values ± SD are shown of an experiment performed in
triplicate, which is representative of three independent experiments. (I) Cells infected in paral-
lel were analysed by flow cytometry 48h and 10 days post-infection to confirm the effect of ral-
tegravir.
(JPG)
S3 Fig. Diagram showing the experimental design used to perform parallel global RNAseq
and integration targeting. Three aliquots of Jurkat cells were independently infected with
VSV-G pseudotyped single cycle HIV-1 LAIΔenv WT or N74D mutant in the presence of
400nM digoxin or DMSO. Thirty-six hours post-infection, nucleic acids were extracted and
used for RNAseq or integration targeting analyses.
(JPG)
S4 Fig. Clustering analysis of RNAseq expressed genes was performed using GeneSpring.
Three aliquots of Jurkat cells were independently infected with VSV-G pseudotyped HIV-1
LAIΔenv WT or N74D mutant in the presence of 400nM digoxin or DMSO. Thirty-six hours
post-infection, nucleic acids were extracted and used for RNAseq. One sample (DMSO WT 1)
did not pass quality control and could not be used for RNAseq.
(JPG)
S5 Fig. Summary of integration site analysis. (A) Summary of integration sites in Jurkat cells
infected with single cycle, VSV-G pseudotyped HIV-1 LAIΔenv WT or N74D at an MOI of 0.2
in the presence of DMSO or 400nM digoxin. Thirty-six hours post-infection, DNA was
extracted, sheared and integration sites quantified using linker-mediated PCR and deep
sequencing. 74, N74D virus; WT, wild type virus. Total clones–the total number of unique
integration sites. Shear Sites–the total number of proviruses detected across all unique integra-
tion sites. Total duplicates–total number of sequencing reads detected across all unique inte-
gration sites. (B-C) Plots showing integration within genes for WT and N74D viruses in the
presence of DMSO (upper panel) or digoxin (lower panel). Each bar in the bar plots describes
the results of an independent experiment. Grey dashed line describes the random expectation
(using in silico generated integration site Files). (B) Plots showing integration within genes.
(C) Focusing on those integrations within host genes, plots showing proviral orientation rela-
tive to the transcriptional start site of cellular genes.
(JPG)
S6 Fig. Digoxin down-regulates expression of CD38 in primary memory CD4+ T-cells. (A)
IPA diagram highlighting genes down-regulated by digoxin that are part of the CD38 pathway.
Continuous lines indicate direct and experimentally validated interactions between genes;
dashed lines indicate experimentally validated, indirect interactions. (B-C) Purified memory
CD4+ T-cells were stimulated via CD3/CD28, cultured for 3 days and exposed to the indicated
concentrations of digoxin for 24h. Cells were labeled with anti-CD38 FITC-conjugated anti-
bodies, stained for cell viability and analyzed by flow cytometry. (B) Representative plot show-
ing the percentage of memory CD4+ T-cells expressing CD38 on their surface in the presence
of the indicated concentrations of digoxin (y-axis). (C) The percentage of CD38 positive cells
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and the MFI was quantified by flow cytometry. Bar graphs represent mean ± SD of 3 donors.
Friedman test p-values are indicated on the graphs: , p<0.05;  p<0.01.
(JPG)
S7 Fig. Model for the selective effect of digoxin. WT virus integrates more frequently than
N74D virus within or near genes implicated in T-cell activation or metabolism, which are
highly expressed in CD4+ T-cells. These genes are susceptible to down regulation by digoxin.
Upon digoxin treatment, the chromatin surrounding these genes becomes repressed, and the
provirus is also repressed in tandem. Silencing of the N74D virus is less likely due to its differ-
ent integration targeting.
(JPG)
S1 File. Results of the selective high through put screening. Plates’ layout: each well was pre-
loaded with the indicated compound at 1 μM. Jurkat cells were exposed to VSV-G pseudo-
typed HIV-1 vector expressing GFP (WT) or mCherry (N74D) in bulk for 1 hour at 4˚C then
identical aliquots added onto each well. Thirty-six hours post-infection, cells were analyzed by
flow cytometry to measure the percentage of GFP+ or mCherry+ cells. The values correspond-
ing to each compound are indicated and color-coded.
(XLSX)
S2 File. RNAseq reads. 250 ng of total RNA was prepared for sequencing following the Illu-
mina TruSeq mRNA (unstranded) protocol, multiplexed, and sequenced (V2 High Output kit,
43bp PE) on an Illumina Nextseq to yield an average of> 15 million reads per sample. Data
was de-multiplexed using bcl2fastq v 2.16. Read QC reports were generated in Illumina Base-
space. Fastq files passing read QC were analysed on the UCL Genomics cluster using an in
house pipeline (Python/R). Sequencing reads were aligned to an appropriate reference genome
using TopHat v2.0.13 and PCR duplicates removed using Picard tools (v1.100). Highlighted in
green are the genes whose expression was changed >4 fold by digoxin.
(XLSX)
S3 File. Ingenuity Pathway Analysis (IPA) of genes up regulated by digoxin. Genes up
regulated> 4 fold by digoxin, as determined by RNAseq, were used to identify specific gene
pathways by IPA.
(XLS)
S4 File. Ingenuity Pathway Analysis (IPA) of genes down regulated by digoxin. Genes
down regulated> 4 fold by digoxin, as determined by RNAseq, were used to identify specific
gene pathways by IPA.
(XLS)
S5 File. List of unique integration sites (UIS). DNA from Jurkat cells, infected with WT or
N74D mutant VSV-G pseudotyped HIV-1 LAIΔenv and treated with 400 nM digoxin or
DMSO, was extracted using Qiagen DNeasy Blood & Tissue kit following the manufacturer’s
instructions. Integration sites were identified and quantified in DNA samples as detailed previ-
ously [47] using the following HIV-specific PCR forward primers: HIVB3 5’-GCTTGCCT
TGAGTGCTTCAAGTAGTGTG-3’, HIVP5B5 5’-AATGATACGGCGACCACCGAGATCT
ACACGTGCCCGTCTGTTGTGTGACTCTGG-3’ and HIV-specific sequencing primer 5’-
ATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTC-3’. Prepared sequencing libraries
were sequenced on the Illumina HiSeq platform. 50 base paired-end reads were aligned to the
human genome (hg19) using the eland_pair implementation of CASAVA.
(XLSX)
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S6 File. Up-regulated genes part of the hereditary and developmental disorder networks.
These genes were up regulated> 4 fold by digoxin according to the RNAseq and formed a sep-
arate IPA network.
(XLS)
S1 Table. List of small compounds that induced a differential infection phenotype in the
high through put screening. These compounds were not validated further.
(DOCX)
Acknowledgments
We thank Richard Jenner, David Selwood, Kathy Kettleborough and Yorifumi Satou for help-
ful discussions, Jane Rasaiyaa for HIV-1 BaL, D. Selwood for the mass spec analyses, MRCT
for the NINDS library, Mike Hubank and Kerra Pearce for support with the RNAseq, Annie
Gosselin for technical help with cell sorting and viral stock production, Paul Kellam and Astrid
Gall for the sequencing of HIV-1 viruses, Mahad Noursadeghi and Lucy Bell for the initial
experiments in primary cells, Clare Jolly and Shimona Starling for the cell-to-cell infection
assays, Alan Engelman and Greg Sowd for the gift of CPSF6 KO cells. We thank Heather Nie-
derer for providing primers and Nirav Malani for bioinformatics advice. We thank Laurence
Game and Marian Dore (Genomics Laboratory, Medical Research Council Clinical Sciences
Centre, Hammersmith Hospital, London, UK) for helpful support. The authors thank Mario
Legault and the HIV/AIDS and Infectious Diseases Network of the Fonds de Recherche Que´-
bec-Sante´ (FRQ-S) for assistance with ethical approvals and informed consents, Jose´e Gir-
ouard and Angie Massicotte (McGill University Health Centre) for their involvement in
patient recruitment and leukapheresis collection, and acknowledge the major contribution to
this work of all study participants.
Author Contributions
Conceptualization: Ariberto Fassati.
Data curation: Anat Melamed, Janos Kriston-Vizi, Ariberto Fassati.
Formal analysis: Alexander Zhyvoloup, Anat Melamed, Janos Kriston-Vizi, Ariberto Fassati.
Funding acquisition: Janos Kriston-Vizi, Robin Ketteler, Petronela Ancuta, Charles R. M.
Bangham, Ariberto Fassati.
Investigation: Alexander Zhyvoloup, Anat Melamed, Ian Anderson, Delphine Planas, Chen-
Hsuin Lee, Ariberto Fassati.
Methodology: Anat Melamed, Ian Anderson.
Project administration: Petronela Ancuta, Charles R. M. Bangham, Ariberto Fassati.
Resources: Andy Merritt, Jean-Pierre Routy.
Software: Anat Melamed.
Supervision: Petronela Ancuta, Charles R. M. Bangham, Ariberto Fassati.
Validation: Alexander Zhyvoloup, Delphine Planas.
Visualization: Alexander Zhyvoloup, Delphine Planas, Petronela Ancuta, Ariberto Fassati.
Writing – original draft: Ariberto Fassati.
Writing – review & editing: Anat Melamed, Petronela Ancuta, Charles R. M. Bangham.
A functional link between HIV-1 integration and T-cell activation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006460 July 20, 2017 24 / 28
References
1. Yamashita M, Emerman M (2004) Capsid is a dominant determinant of retrovirus infectivity in nondivid-
ing cells. J Virol 78: 5670–5678. https://doi.org/10.1128/JVI.78.11.5670-5678.2004 PMID: 15140964
2. Fassati A (2012) Multiple roles of the capsid protein in the early steps of HIV-1 infection. Virus Res.
3. Di Nunzio F, Fricke T, Miccio A, Valle-Casuso JC, Perez P, et al. (2013) Nup153 and Nup98 bind the
HIV-1 core and contribute to the early steps of HIV-1 replication. Virology 440: 8–18. https://doi.org/10.
1016/j.virol.2013.02.008 PMID: 23523133
4. Matreyek KA, Yucel SS, Li X, Engelman A (2013) Nucleoporin NUP153 phenylalanine-glycine motifs
engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS
Pathog 9: e1003693. https://doi.org/10.1371/journal.ppat.1003693 PMID: 24130490
5. Price AJ, Jacques DA, McEwan WA, Fletcher AJ, Essig S, et al. (2014) Host Cofactors and Pharmaco-
logic Ligands Share an Essential Interface in HIV-1 Capsid That Is Lost upon Disassembly. PLoS patho-
gens 10: e1004459. https://doi.org/10.1371/journal.ppat.1004459 PMID: 25356722
6. Bhattacharya A, Alam SL, Fricke T, Zadrozny K, Sedzicki J, et al. (2014) Structural basis of HIV-1 cap-
sid recognition by PF74 and CPSF6. Proc Natl Acad Sci U S A 111: 18625–18630. https://doi.org/10.
1073/pnas.1419945112 PMID: 25518861
7. Schaller T, Ocwieja KE, Rasaiyaah J, Price AJ, Brady TL, et al. (2011) HIV-1 capsid-cyclophilin interac-
tions determine nuclear import pathway, integration targeting and replication efficiency. PLoS patho-
gens 7: e1002439. https://doi.org/10.1371/journal.ppat.1002439 PMID: 22174692
8. Bichel K, Price AJ, Schaller T, Towers GJ, Freund SM, et al. (2013) HIV-1 capsid undergoes coupled
binding and isomerization by the nuclear pore protein NUP358. Retrovirology 10: 81. https://doi.org/10.
1186/1742-4690-10-81 PMID: 23902822
9. Di Nunzio F, Danckaert A, Fricke T, Perez P, Fernandez J, et al. (2012) Human nucleoporins promote
HIV-1 docking at the nuclear pore, nuclear import and integration. PLoS One 7: e46037. https://doi.org/
10.1371/journal.pone.0046037 PMID: 23049930
10. Meehan AM, Saenz DT, Guevera R, Morrison JH, Peretz M, et al. (2014) A cyclophilin homology
domain-independent role for Nup358 in HIV-1 infection. PLoS pathogens 10: e1003969. https://doi.org/
10.1371/journal.ppat.1003969 PMID: 24586169
11. Christ F, Thys W, De Rijck J, Gijsbers R, Albanese A, et al. (2008) Transportin-SR2 imports HIV into the
nucleus. Curr Biol 18: 1192–1202. https://doi.org/10.1016/j.cub.2008.07.079 PMID: 18722123
12. Krishnan L, Matreyek KA, Oztop I, Lee K, Tipper CH, et al. (2010) The requirement for cellular transpor-
tin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and
not integrase. J Virol 84: 397–406. https://doi.org/10.1128/JVI.01899-09 PMID: 19846519
13. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008) Identification of host proteins
required for HIV infection through a functional genomic screen. Science 319: 921–926. https://doi.org/
10.1126/science.1152725 PMID: 18187620
14. De Iaco A, Luban J (2011) Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and
detectable after viral cDNA enters the nucleus. Retrovirology 8: 98. https://doi.org/10.1186/1742-4690-
8-98 PMID: 22145813
15. Zhou L, Sokolskaja E, Jolly C, James W, Cowley SA, et al. (2011) Transportin 3 Promotes a Nuclear
Maturation Step Required for Efficient HIV-1 Integration. PLoS Pathog 7: e1002194. https://doi.org/10.
1371/journal.ppat.1002194 PMID: 21901095
16. Vozzolo L, Loh B, Gane PJ, Tribak M, Zhou L, et al. (2010) Gyrase B inhibitor impairs HIV-1 replication
by targeting Hsp90 and the capsid protein. J Biol Chem 285: 39314–39328. https://doi.org/10.1074/jbc.
M110.155275 PMID: 20937817
17. Peng K, Muranyi W, Glass B, Laketa V, Yant SR, et al. (2014) Quantitative microscopy of functional HIV
post-entry complexes reveals association of replication with the viral capsid. Elife 3: e04114. https://
doi.org/10.7554/eLife.04114 PMID: 25517934
18. Hulme AE, Kelley Z, Foley D, Hope TJ (2015) Complementary Assays Reveal a Low Level of CA Asso-
ciated with Viral Complexes in the Nuclei of HIV-1-Infected Cells. J Virol 89: 5350–5361. https://doi.org/
10.1128/JVI.00476-15 PMID: 25741002
19. Chin CR, Perreira JM, Savidis G, Portmann JM, Aker AM, et al. (2015) Direct Visualization of HIV-1
Replication Intermediates Shows that Capsid and CPSF6 Modulate HIV-1 Intra-nuclear Invasion and
Integration. Cell Rep 13: 1717–1731. https://doi.org/10.1016/j.celrep.2015.10.036 PMID: 26586435
20. Chen NY, Zhou L, Gane PJ, Opp S, Ball NJ, et al. (2016) HIV-1 capsid is involved in post-nuclear entry
steps. Retrovirology 13: 28. https://doi.org/10.1186/s12977-016-0262-0 PMID: 27107820
21. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, et al. (2002) HIV-1 integration in the human genome
favors active genes and local hotspots. Cell 110: 521–529. PMID: 12202041
A functional link between HIV-1 integration and T-cell activation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006460 July 20, 2017 25 / 28
22. Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD (2007) HIV integration site selection: analysis by
massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res 17:
1186–1194. https://doi.org/10.1101/gr.6286907 PMID: 17545577
23. Sowd GA, Serrao E, Wang H, Wang W, Fadel HJ, et al. (2016) A critical role for alternative polyadenyla-
tion factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. Proc Natl Acad Sci
U S A 113: E1054–1063. https://doi.org/10.1073/pnas.1524213113 PMID: 26858452
24. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, et al. (2005) A role for LEDGF/p75 in targeting
HIV DNA integration. Nat Med 11: 1287–1289. https://doi.org/10.1038/nm1329 PMID: 16311605
25. Ocwieja KE, Brady TL, Ronen K, Huegel A, Roth SL, et al. (2011) HIV integration targeting: a pathway
involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog 7: e1001313. https://doi.
org/10.1371/journal.ppat.1001313 PMID: 21423673
26. Laird GM, Eisele EE, Rabi SA, Nikolaeva D, Siliciano RF (2014) A novel cell-based high-throughput
screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides. J Antimi-
crob Chemother 69: 988–994. https://doi.org/10.1093/jac/dkt471 PMID: 24275119
27. Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, et al. (2010) Flexible use of nuclear import pathways by
HIV-1. Cell Host Microbe 7: 221–233. https://doi.org/10.1016/j.chom.2010.02.007 PMID: 20227665
28. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, et al. (2013) HIV-1 evades innate immune
recognition through specific cofactor recruitment. Nature 503: 402–405. https://doi.org/10.1038/
nature12769 PMID: 24196705
29. Wong RW, Balachandran A, Ostrowski MA, Cochrane A (2013) Digoxin suppresses HIV-1 replication
by altering viral RNA processing. PLoS Pathog 9: e1003241. https://doi.org/10.1371/journal.ppat.
1003241 PMID: 23555254
30. Laird GM, Eisele EE, Rabi SA, Nikolaeva D, Siliciano RF (2013) A novel cell-based high-throughput
screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides. J Antimi-
crob Chemother.
31. Aguilar-Cordova E, Chinen J, Donehower L, Lewis DE, Belmont JW (1994) A sensitive reporter cell line
for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. AIDS Res Hum Retroviruses 10:
295–301. https://doi.org/10.1089/aid.1994.10.295 PMID: 8018390
32. Spits H, Di Santo JP (2011) The expanding family of innate lymphoid cells: regulators and effectors of
immunity and tissue remodeling. Nat Immunol 12: 21–27. https://doi.org/10.1038/ni.1962 PMID:
21113163
33. Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361:
888–898. https://doi.org/10.1056/NEJMra0707449 PMID: 19710487
34. Paula S, Tabet MR, Ball WJ Jr. (2005) Interactions between cardiac glycosides and sodium/potassium-
ATPase: three-dimensional structure-activity relationship models for ligand binding to the E2-Pi form of
the enzyme versus activity inhibition. Biochemistry 44: 498–510. https://doi.org/10.1021/bi048680w
PMID: 15641774
35. Brown BT, Stafford A, Wright SE (1962) Chemical structure and pharmacological activity of some deriv-
atives of digitoxigenin and digoxigenin. Br J Pharmacol Chemother 18: 311–324. PMID: 13873586
36. Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, et al. (2011) Digoxin and its derivatives suppress
TH17 cell differentiation by antagonizing RORgammat activity. Nature 472: 486–490. https://doi.org/
10.1038/nature09978 PMID: 21441909
37. Fujita-Sato S, Ito S, Isobe T, Ohyama T, Wakabayashi K, et al. (2011) Structural basis of digoxin that
antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin
(IL)-17 production. J Biol Chem 286: 31409–31417. https://doi.org/10.1074/jbc.M111.254003 PMID:
21733845
38. Laursen M, Gregersen JL, Yatime L, Nissen P, Fedosova NU (2015) Structures and characterization of
digoxin- and bufalin-bound Na+,K+-ATPase compared with the ouabain-bound complex. Proc Natl
Acad Sci U S A 112: 1755–1760. https://doi.org/10.1073/pnas.1422997112 PMID: 25624492
39. Price EM, Lingrel JB (1988) Structure-function relationships in the Na,K-ATPase alpha subunit: site-
directed mutagenesis of glutamine-111 to arginine and asparagine-122 to aspartic acid generates a
ouabain-resistant enzyme. Biochemistry 27: 8400–8408. PMID: 2853965
40. Hazuda D, Iwamoto M, Wenning L (2009) Emerging pharmacology: inhibitors of human immunodefi-
ciency virus integration. Annu Rev Pharmacol Toxicol 49: 377–394. https://doi.org/10.1146/annurev.
pharmtox.011008.145553 PMID: 18928385
41. Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, et al. (2006) Lentiviral vectors with a defective
integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S
A 103: 17684–17689. https://doi.org/10.1073/pnas.0606197103 PMID: 17095605
A functional link between HIV-1 integration and T-cell activation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006460 July 20, 2017 26 / 28
42. Sloan RD, Donahue DA, Kuhl BD, Bar-Magen T, Wainberg MA (2010) Expression of Nef from uninte-
grated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes. Retrovirology 7:
44. https://doi.org/10.1186/1742-4690-7-44 PMID: 20465832
43. Haas M, Wang H, Tian J, Xie Z (2002) Src-mediated inter-receptor cross-talk between the Na+/K
+-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated
protein kinases. J Biol Chem 277: 18694–18702. https://doi.org/10.1074/jbc.M111357200 PMID:
11907028
44. Aizman O, Uhlen P, Lal M, Brismar H, Aperia A (2001) Ouabain, a steroid hormone that signals with
slow calcium oscillations. Proc Natl Acad Sci U S A 98: 13420–13424. https://doi.org/10.1073/pnas.
221315298 PMID: 11687608
45. Shaulian E, Karin M (2001) AP-1 in cell proliferation and survival. Oncogene 20: 2390–2400. https://
doi.org/10.1038/sj.onc.1204383 PMID: 11402335
46. Melamed A, Laydon DJ, Gillet NA, Tanaka Y, Taylor GP, et al. (2013) Genome-wide determinants of
proviral targeting, clonal abundance and expression in natural HTLV-1 infection. PLoS Pathog 9:
e1003271. https://doi.org/10.1371/journal.ppat.1003271 PMID: 23555266
47. Gillet NA, Malani N, Melamed A, Gormley N, Carter R, et al. (2011) The host genomic environment of
the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood 117: 3113–3122.
https://doi.org/10.1182/blood-2010-10-312926 PMID: 21228324
48. Van Lint C, Bouchat S, Marcello A (2013) HIV-1 transcription and latency: an update. Retrovirology 10:
67. https://doi.org/10.1186/1742-4690-10-67 PMID: 23803414
49. Frauwirth KA, Thompson CB (2004) Regulation of T lymphocyte metabolism. J Immunol 172: 4661–
4665. PMID: 15067038
50. van der Windt GJ, Pearce EL (2012) Metabolic switching and fuel choice during T-cell differentiation
and memory development. Immunol Rev 249: 27–42. https://doi.org/10.1111/j.1600-065X.2012.
01150.x PMID: 22889213
51. Hegedus A, Kavanagh Williamson M, Huthoff H (2014) HIV-1 pathogenicity and virion production are
dependent on the metabolic phenotype of activated CD4+ T cells. Retrovirology 11: 98. https://doi.org/
10.1186/s12977-014-0098-4 PMID: 25421745
52. Singh PK, Plumb MR, Ferris AL, Iben JR, Wu X, et al. (2015) LEDGF/p75 interacts with mRNA splicing
factors and targets HIV-1 integration to highly spliced genes. Genes Dev 29: 2287–2297. https://doi.
org/10.1101/gad.267609.115 PMID: 26545813
53. Malavasi F, Funaro A, Alessio M, DeMonte LB, Ausiello CM, et al. (1992) CD38: a multi-lineage cell acti-
vation molecule with a split personality. Int J Clin Lab Res 22: 73–80. PMID: 1504309
54. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, et al. (2009) Molecular mechanism and function
of CD40/CD40L engagement in the immune system. Immunol Rev 229: 152–172. https://doi.org/10.
1111/j.1600-065X.2009.00782.x PMID: 19426221
55. Brenner B, Koppenhoefer U, Lepple-Wienhues A, Grassme H, Muller C, et al. (1997) The CD40 ligand
directly activates T-lymphocytes via tyrosine phosphorylation dependent PKC activation. Biochem Bio-
phys Res Commun 239: 11–17. https://doi.org/10.1006/bbrc.1997.7415 PMID: 9345261
56. Hsu YM, Lucci J, Su L, Ehrenfels B, Garber E, et al. (1997) Heteromultimeric complexes of CD40 ligand
are present on the cell surface of human T lymphocytes. J Biol Chem 272: 911–915. PMID: 8995381
57. Tchasovnikarova IA, Timms RT, Matheson NJ, Wals K, Antrobus R, et al. (2015) GENE SILENCING.
Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells. Science
348: 1481–1485. https://doi.org/10.1126/science.aaa7227 PMID: 26022416
58. Lusic M, Marcello A, Cereseto A, Giacca M (2003) Regulation of HIV-1 gene expression by histone
acetylation and factor recruitment at the LTR promoter. Embo J 22: 6550–6561. https://doi.org/10.
1093/emboj/cdg631 PMID: 14657027
59. Jordan A, Defechereux P, Verdin E (2001) The site of HIV-1 integration in the human genome deter-
mines basal transcriptional activity and response to Tat transactivation. Embo J 20: 1726–1738. https://
doi.org/10.1093/emboj/20.7.1726 PMID: 11285236
60. El Kharroubi A, Piras G, Zensen R, Martin MA (1998) Transcriptional activation of the integrated chro-
matin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 18: 2535–2544. PMID:
9566873
61. Van Lint C, Emiliani S, Ott M, Verdin E (1996) Transcriptional activation and chromatin remodeling of
the HIV-1 promoter in response to histone acetylation. Embo J 15: 1112–1120. PMID: 8605881
62. Verdin E, Paras P Jr., Van Lint C (1993) Chromatin disruption in the promoter of human immunodefi-
ciency virus type 1 during transcriptional activation. Embo J 12: 3249–3259. PMID: 8344262
A functional link between HIV-1 integration and T-cell activation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006460 July 20, 2017 27 / 28
63. Benkirane M, Chun RF, Xiao H, Ogryzko VV, Howard BH, et al. (1998) Activation of integrated provirus
requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem 273:
24898–24905. PMID: 9733796
64. Marini B, Kertesz-Farkas A, Ali H, Lucic B, Lisek K, et al. (2015) Nuclear architecture dictates HIV-1
integration site selection. Nature 521: 227–231. https://doi.org/10.1038/nature14226 PMID: 25731161
65. Lelek M, Casartelli N, Pellin D, Rizzi E, Souque P, et al. (2015) Chromatin organization at the nuclear
pore favours HIV replication. Nat Commun 6: 6483. https://doi.org/10.1038/ncomms7483 PMID:
25744187
66. Brady T, Agosto LM, Malani N, Berry CC, O’Doherty U, et al. (2009) HIV integration site distributions in
resting and activated CD4+ T cells infected in culture. Aids 23: 1461–1471. https://doi.org/10.1097/
QAD.0b013e32832caf28 PMID: 19550285
67. Vatakis DN, Kim S, Kim N, Chow SA, Zack JA (2009) Human immunodeficiency virus integration effi-
ciency and site selection in quiescent CD4+ T cells. J Virol 83: 6222–6233. https://doi.org/10.1128/JVI.
00356-09 PMID: 19369341
68. Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, et al. (2004) Resting CD4+ T cells from human
immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within
actively transcribed host genes. J Virol 78: 6122–6133. https://doi.org/10.1128/JVI.78.12.6122-6133.
2004 PMID: 15163705
69. Soto MJ, Pena A, Vallejo FG (2011) A genomic and bioinformatics analysis of the integration of HIV in
peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 27: 547–555. https://doi.org/10.1089/
aid.2010.0182 PMID: 20919923
70. Mack KD, Jin X, Yu S, Wei R, Kapp L, et al. (2003) HIV insertions within and proximal to host cell genes
are a common finding in tissues containing high levels of HIV DNA and macrophage-associated p24
antigen expression. J Acquir Immune Defic Syndr 33: 308–320. PMID: 12843741
71. Chang CH, Pearce EL (2016) Emerging concepts of T cell metabolism as a target of immunotherapy.
Nat Immunol 17: 364–368. https://doi.org/10.1038/ni.3415 PMID: 27002844
72. Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS (2015) A hardwired HIV latency program. Cell
160: 990–1001. https://doi.org/10.1016/j.cell.2015.02.009 PMID: 25723172
73. Vranckx LS, Demeulemeester J, Saleh S, Boll A, Vansant G, et al. (2016) LEDGIN-mediated Inhibition
of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV. EBioMedicine 8:
248–264. https://doi.org/10.1016/j.ebiom.2016.04.039 PMID: 27428435
74. Cutino-Moguel T, Fassati A (2006) A phenotypic recessive, post-entry block in rabbit cells that results in
aberrant trafficking of HIV-1. Traffic 7: 978–992. https://doi.org/10.1111/j.1600-0854.2006.00449.x
PMID: 16882040
75. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM (2004) Dynamics of HIV-1 recombination in its natural
target cells. Proc Natl Acad Sci U S A 101: 4204–4209. https://doi.org/10.1073/pnas.0306764101
PMID: 15010526
76. Van Parijs L, Refaeli Y, Lord JD, Nelson BH, Abbas AK, et al. (1999) Uncoupling IL-2 signals that regu-
late T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11: 281–
288. PMID: 10514006
77. Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said EA, et al. (2010) Peripheral blood CCR4
+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol 184:
1604–1616. https://doi.org/10.4049/jimmunol.0903058 PMID: 20042588
78. Monteiro P, Gosselin A, Wacleche VS, El-Far M, Said EA, et al. (2011) Memory CCR6+CD4+ T cells
are preferential targets for productive HIV type 1 infection regardless of their expression of integrin
beta7. J Immunol 186: 4618–4630. https://doi.org/10.4049/jimmunol.1004151 PMID: 21398606
79. Wacleche VS, Chomont N, Gosselin A, Monteiro P, Goupil M, et al. (2012) The colocalization potential
of HIV-specific CD8+ and CD4+ T-cells is mediated by integrin beta7 but not CCR6 and regulated by
retinoic acid. PloS one 7: e32964. https://doi.org/10.1371/journal.pone.0032964 PMID: 22470433
80. Chattopadhyay PK, Yu J, Roederer M (2006) Live-cell assay to detect antigen-specific CD4+ T-cell
responses by CD154 expression. Nat Protoc 1: 1–6. https://doi.org/10.1038/nprot.2006.1 PMID:
17406204
81. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, et al. (2004) The UCSC Table Browser
data retrieval tool. Nucleic Acids Res 32: D493–496. https://doi.org/10.1093/nar/gkh103 PMID:
14681465
82. Malani N (2013) hiAnnotator: Functions for annotating GRanges objects. R package version 1.6.2 ed:
Bioconductor.
A functional link between HIV-1 integration and T-cell activation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006460 July 20, 2017 28 / 28
